Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Bullboard - Stock Discussion Forum Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s): MEDXF

Healthcare

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its... see more

Add To Watchlist

Bullboard (TSX:MDP)

View:

Comment by Napcooon Mar 28, 2024 6:15pm

RE:Ixinity replacement therapy

How much they've spent on ixinity? A lot, https://hemophilianewstoday.com/news/in-potential-100m-deal-medexus-acquires-global-rights-to-ixinity-hemophilia-b-therapy/ Rasuvu facing ...more

Discussion

Post by Napcooon Mar 28, 2024 6:08pm

Ixinity replacement therapy

Cost per patient per year should be above $200k, while Gene therapy should be above $2mln, per person, one time cost, this is why MDP withdraw some sales for ixinity. Predicting 5% drop in sales, it ...more

151

Discussion

Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million

posted Nov 21, 2024 9:00am by Innocan Pharma Corp

"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more

(0)
•••

Post by PressReleaseon Mar 26, 2024 7:54am

New Press Release - FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age groupToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF...read article.

Comment by Napcooon Mar 24, 2024 5:07pm

RE:RE:RE:Cash 8 mln on Dec 31, 2023

Busulfan is generalized, similar to treosulfan, and FDA approved the generalized busulfan in USA, the peak busulfan yearly revenue was $120 mln in USA in 2016, if Treo was approved, it had to complete ...more

Discussion

Comment by Napcooon Mar 24, 2024 4:47pm

RE:RE:Cash 8 mln on Dec 31, 2023

Another $100 mln treosulfan deal, $5 mln upfront, $55 mln milestone payment, $40 mln sales milestone payment. Great deal then, not sure it is worth it today https://www.medexus.com/en_US ...more

Discussion

Comment by Napcooon Mar 24, 2024 4:38pm

RE:Cash 8 mln on Dec 31, 2023

Medexus reverse took over pediapharm, and buy medac pharm for $50 Mon USD in 2018 with rasuvo, a good deal https://mergr.com/medexus-pharmaceuticals-acquires-medac-pharma

Discussion

Comment by Napcooon Mar 24, 2024 4:21pm

RE:RE:Cash 8 mln on Dec 31, 2023

40 to $100 mln deal does not look great today https://hemophilianewstoday.com/news/in-potential-100m-deal-medexus-acquires-global-rights-to-ixinity-hemophilia-b-therapy/

Discussion

Comment by Napcooon Mar 24, 2024 3:51pm

RE:Cash 8 mln on Dec 31, 2023

Hemophilia b market, replacement therapy like ixinity, will be replaced by others gradually and eventually https://www.delveinsight.com/blog/hemophilia-b-market

Discussion

Comment by Napcooon Mar 23, 2024 8:05pm

RE:RE:I think people r over reacting ...

The sales were hired for the treo launch, and assigned to other products, they were desperate to increase revenue to be able to be able to refinance with BMO, and raise by selling shares, now that the ...more

Discussion

Comment by Napcooon Mar 13, 2024 6:29pm

RE:Cash 8 mln on Dec 31, 2023

$1.68 now, it is even worse to raise at lower price, why?

Discussion

Post by Napcooon Mar 03, 2024 5:23pm

Cash 8 mln on Dec 31, 2023

Expenses per quarter 12 mln, with some credit facility to use, sales peaked, Treo will be the last momentum, a raise is possible, 1.82 is still a good price to raise

167

Discussion

Comment by zwerp2000on Feb 21, 2024 9:40am

RE:I think people r over reacting ...

You're missing the big picture. Their big revenue driver, IXINITY, is getting slashed big time. So much so they are materially cutting salesforce and efforts to sell it. That is not good at ...more

135

Discussion